Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases
Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches.
Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.
Current Team (6)Update
Funding Rounds (6) - $63MUpdate
Board Members and Advisors (7)Update
Shire PLC is a specialty biopharmaceutical company. They have a global sales and marketing...
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Venture capital Firm
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life...
Morgenthaler Ventures is a venture capital and private equity firm that invests in IT and life...
Fibrotic Ventures was added to CrunchBase in 2012
Trellis Bioscience is a therapeutic antibody company developing treatments for infectious...
101 Hartwell Avenue
Lexington, MA 02421